Scientific Workshop on T-Cell Acute Lymphoblastic Leukemia

DATES: March 22-24, 2013

LOCATION: Lisbon, Portugal

CHAIRS: J Cools, A Ferrando, J Meijerink, J Soulier

EHA-ESH Scientific Workshops present state-of-the-art science. This workshop promotes informal interaction and discussion between scientists and clinicians working in the field.

This workshop will cover the following topics:

Normal and leukemic development in the thymus
High-throughput genetics and epigenomics; expression analysis in T-ALL
Clonal evolution and relapse in T-ALL
Signaling pathways in normal and leukemic T-cells (Notch, IL7 and others)
In vitro and in vivo models of T-cell oncogenesis
Prognostic markers, minimal reidual disease
Clinical T-ALL trial update, new T-ALL therapy (new drugs, targeted therapy)

Registration

Online registration will open through the website of the European School of Haematology: www.esh.org

Registration Fee*

Early Bird 560 euros
Regular (one month before the meeting starts) 695 euros
On site 795 euros

* Registration fee includes teaching material and lunch

CME Accreditation

The programme of the ESH-EHA Scientific Workshop on T-Cell Acute Lymphoblastic Leukemia has been reviewed and approved for CME accreditation by the European Hematology Association CME Unit. The EHA-CME Unit has approved this educational activity for a maximum number of CME credits. Each physician should only claim credits for time that she/he actually spent in the educational activity.

SPONSOR OPPORTUNITIES:

Several sponsor opportunities for this particular event have been created. For sponsor opportunities please contact Ghyslaine Lebougault at the European School of Haematology. Email: ghyslaine.lebougault@univ-paris-diderot.fr Telephone: + 33(0)1 57 27 67 39, Fax: + 33(0)1 57 27 68 38

Program

Friday, March 22, 2013

Time	Title	Speaker
15:50-16:00	Welcome to the participants
	SESSION I – NORMAL AND LEUKEMIC LYMPHOID DEVELOPMENT IN THE THYMUS	Chairs: I Aifantis, AFerrando
16:00-16:40	Keynote Lecture 1: “Transcriptional regulation of early T-cell development: negotiating a leap between regulatory states”	EV Rothenberg
16:40-17:10	Hedgehog signalling in T-cell development and differentiation	T Crompton
17:10-17:40	TLX-ETS1 mediated TCRa block of maturation in T-ALL	V Asnafi
17:40-18:00	Coffee break
	Chairs: J Aster, J Barata
18:00-18:30	Notch signalling in normal and malignant T cells	F Radtke
18:30-18:45	Specific Notch receptor/ligand interactions control human TCRαβ and γδT cell development by inducing differential Notch signal strength	I Van de Walle
18:45-19:00	The TAL1 Complex Targets the FBXW7 Tumor Suppressor by activating miR-223 in Human T-ALL	M Mansour
19:00-19:15	Overexpression of Zeb2 results in a block in T cell development and identifies this gene as a new driver for T-ALL	S Goossens
20:15	Dinner

Saturday, March 23, 2013

Saturday, March 23, 2013

Time	Title	Speaker
	SESSION II – GENOMICS AND ONCOGENIC NETWORKS IN T-ALL	Chairs: S Hunger and J van Dongen
08:30-09:00	Molecular-genetic characterization of T-cell ALL	J P Meijerink
09:00-09:30	Exome sequencing and RNA-sequencing in T-ALL	J Cools
09:30-10:00	Genomic and functional profiling of T-ALL progression	J Soulier
10:00-10:15	H3K27me3 erasers are novel targets in T-ALL	J van den Meulen
10:15-10:30	Interrogating the clonal architecture of SIL-TAL1 T-ALL with multicolour FISH	C Furness
10:30-11:00	Coffee break
	SESSION III – SIGNALING PATHWAYS; LEUKEMIC T CELLS	Chairs: M Kelliher and J Meijerink
11:00-11:30	Signaling networks, targeted therapies and drug resistance in T-ALL	A A Ferrando
11:30-12:00	IL-7 and IL-7R-mediated signaling in T-ALL	J T Barata
12:00-12:15	Inhibition of IL-7R as a novel targeted therapy against T-ALL	M L Toribio
12:15-12:30	The pro-inflammatory IL18 cytokine produced by bone marrow derived stromal cells participates into T-ALL progression	F Pflumio
12:30-14:00	Lunch
	SESSION IV – CLINICAL T-ALL TRIALS, NEW THERAPIES, BIOMARKERS	Chairs: G Martinelli and H Dombret
14:00-14:30	Current and future therapy for pediatric T-ALL	S Hunger
14:30-15:00	Adult T-ALL: Clinical Trials, Risk Stratification, New Therapies	H Dombret
15:00-15:15	Prognostic relevance of integrated genetic profiling in adult T-ALL	P Van Vlierberghe
15:15-15:40	Coffee break
15:40-16:10	Assessment of treatment effectiveness and occurrence of relapse in T-ALL	J van Dongen
16:10-16:40	Nearest neighbours to T-ALL (AML, peripheral T-NHL, T-LBL)	E Macintyre
16:40-16:55	Preclinical activity of a novel inhibitor of NOTCH transcriptional activation in T-ALL samples from patients with high resistant disease	V Frismantas
17:00-19:30	POSTER SESSION WITH THE AUTHORS
20:15	Dinner

Sunday, March 24, 2013

Time	Title	Speaker
	SESSION V – IN VITRO AND IN VIVO T-ALL MODELS, ONCOGENIC NETWORKS, MISCELLANEOUS	Chairs: F Radtke and J Soulier
09:00-09:40	Keynote Lecture 2: Lessons from animal modeling: post-translational and epigenetic modification of T-ALL stem cell activity	I Aifantis
09:40-10:10	Targeting c-Myc in the T-ALL Leukemia-Initiating Cells	M Kelliher
10:10-10:25	MicroRNA action in T-cell leukemia	H G Wendel
10:25-10:40	CNOT3 is mutated in T-ALL and is a tumor suppressor gene in a Drosophila eye cancer model	C Vicente
10:40-11:10	Coffee break
	Chairs: J Barata and J Cools
11:10-11:40	Regulation of Target Gene Expression by Notch1 in T-ALL Cells	J Aster
11:40-12:10	Wnt signaling in T-ALL	J Ghysdael
12:10-12:25	Thymocyte reprogramming by the Scl, Lmo1 and Notch1 oncogenes in mice	B Gerby
12:25-12:40	TK signaling, Notch and PTEN loss converge on mTOR in a murine T‐ALL model and cause addiction to cap dependent mRNA translation	A Schwarzer
12:40	Conference closure by the co-chairs
13:00-14:30	Lunch
	END OF THE MEETING